Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

被引：47
|
作者：
Kudo, Masatoshi [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan
来源：
LIVER CANCER | 2022年 / 11卷 / 05期
关键词：
Atezolizumab plus bevacizumab; Hepatocellular carcinoma; ABC conversion; Curative therapy; Cancer-free status; Drug-free status; POSITRON-EMISSION-TOMOGRAPHY; T-CELL RESPONSES; RADIOFREQUENCY ABLATION; F-18-FDG PET/CT; TUMOR; LENVATINIB; DIFFERENTIATION; IDENTIFICATION; ENHANCEMENT; MULTICENTER;
D O I：
10.1159/000526163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：399 / 406
页数：8
相关论文
共 50 条
  • [31] Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishikawa, Hiroki
    Nishimura, Takashi
    Kawata, Kazuhito
    Kosaka, Hisashi
    Naganuma, Atsushi
    Yata, Yutaka
    Ohama, Hideko
    Kuroda, Hidekatsu
    Matono, Tomomitsu
    Aoki, Tomoko
    Kanayama, Yuki
    Tanaka, Kazunari
    Tada, Fujimasa
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Nakamura, Shinichiro
    Enomoto, Hirayuki
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (10) : 1361 - 1373
  • [32] Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture
    Miyata, Tatsunori
    Sugi, Kazuhiro
    Horino, Taichi
    Ono, Asuka
    Tagayasu, Yoshiyuki
    Nomoto, Daichi
    Inoue, Mitsuhiro
    Mizumoto, Takao
    Kubota, Tatsuo
    Yanagida, Eriko
    Murayama, Toshihiko
    Miyanari, Nobutomo
    Baba, Hideo
    ANTICANCER RESEARCH, 2023, 43 (02) : 943 - 947
  • [33] Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
    Hatanaka, Takeshi
    Yata, Yutaka
    Naganuma, Atsushi
    Kakizaki, Satoru
    CANCERS, 2023, 15 (06)
  • [34] Response prediction model of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: multicenter retrospective study
    Ueno, Masaki
    Kosaka, Hisashi
    Iida, Hiroya
    Ida, Yoshiyuki
    Aoi, Kazunori
    Mori, Haruki
    Miyamoto, Atsushi
    Nishida, Yuko
    Hayami, Shinya
    Kawai, Manabu
    Kaibori, Masaki
    ONCOLOGY, 2023, 101 (09) : 565 - 574
  • [35] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
    Zhang, Xin
    Wang, Jingjing
    Shi, Juanjuan
    Jia, Xiaoli
    Dang, Shuangsuo
    Wang, Wenjun
    JAMA NETWORK OPEN, 2021, 4 (04)
  • [36] OPTIMAL MANAGEMENT OF ATEZOLIZUMAB PLUS BEVACIZUMAB THERAPY FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA FOCUSING ON THERAPEUTIC MODIFICATIONS
    Tokunaga, Takayuki
    Tateyama, Masakuni
    Kondo, Yasuteru
    Miuma, Satoshi
    Miyase, Shiho
    Tanaka, Kentaro
    Narahara, Satoshi
    Inada, Hiroki
    Kurano, Sotaro
    Yoshimaru, Yoko
    Nagaoka, Katsuya
    Watanabe, Takehisa
    Setoyama, Hiroko
    Tanaka, Yasuhito
    HEPATOLOGY, 2022, 76 : S1351 - S1352
  • [37] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
    Mah I Kan Changez
    Maimoona Khan
    Muhammad Uzair
    Muhammad Fawad Tahir
    Maryam Mohsin
    Amna Faiyaz Hussain
    Vania Saqib
    Muhammad Khizer Molani
    Aisha Habib Ahmed
    Saad Khalid
    Journal of Gastrointestinal Cancer, 2024, 55 : 467 - 481
  • [38] Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Kariyama, Kazuya
    Tani, Joji
    Hirooka, Masashi
    Takaguchi, Koichi
    Atsukawa, Masanori
    Fukunishi, Shinya
    Itobayashi, Ei
    Tsuji, Kunihiko
    Tajiri, Kazuto
    Ochi, Hironori
    Ishikawa, Toru
    Yasuda, Satoshi
    Ogawa, Chikara
    Toyoda, Hidenori
    Hatanaka, Takeshi
    Nishimura, Takashi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Shimada, Noritomo
    Tada, Fujimasa
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Ohama, Hideko
    Morishita, Asahiro
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Kosaka, Hisashi
    Imai, Michitaka
    Naganuma, Atsushi
    Nakamura, Shinichiro
    Koizumi, Yohei
    Matono, Tomomitsu
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    ONCOLOGY, 2023, 101 (04) : 270 - 281
  • [39] Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices
    Fujimasa Tada
    Atsushi Hiraoka
    Toshifumi Tada
    Masashi Hirooka
    Kazuya Kariyama
    Joji Tani
    Masanori Atsukawa
    Koichi Takaguchi
    Ei Itobayashi
    Shinya Fukunishi
    Kunihiko Tsuji
    Toru Ishikawa
    Kazuto Tajiri
    Hironori Ochi
    Hidenori Toyoda
    Chikara Ogawa
    Takashi Nishimura
    Takeshi Hatanaka
    Satoru Kakizaki
    Noritomo Shimada
    Kazuhito Kawata
    Atsushi Naganuma
    Hisashi Kosaka
    Tomomitsu Matono
    Hidekatsu Kuroda
    Yutaka Yata
    Hideko Ohama
    Kazuhiro Nouso
    Asahiro Morishita
    Akemi Tsutsui
    Takuya Nagano
    Norio Itokawa
    Tomomi Okubo
    Taeang Arai
    Keisuke Yokohama
    Hiroki Nishikawa
    Michitaka Imai
    Yohei Koizumi
    Shinichiro Nakamura
    Hiroko Iijima
    Masaki Kaibori
    Yoichi Hiasa
    Takashi Kumada
    Journal of Gastroenterology, 2023, 58 : 1134 - 1143
  • [40] FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
    Casak, Sandra J.
    Donoghue, Martha
    Fashoyin-Aje, Lola
    Jiang, Xiaoping
    Rodriguez, Lisa
    Shen, Yuan-Li
    Xu, Yuan
    Jiang, Xiling
    Liu, Jiang
    Zhao, Hong
    Pierce, William F.
    Mehta, Shubhangi
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Kluetz, Paul G.
    Pazdur, Richard
    Lemery, Steven J.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1836 - 1841
12345